Chikungunya Vaccine Live

Chikungunya vaccine, live is indicated for prevention of disease caused by chikungunya virus (CHIKV) in individuals aged 18 years and older who are at increased risk of exposure to CHIKV.

• Chikungunya vaccine, live is available under the following different brand names: Ixchiq.

Common side effects of Chikungunya vaccine, live include:

• headache 
• fatigue
• muscle pain 
• joint pain 
• fever
• nausea and tenderness at the injection site

Serious side effects of Chikungunya vaccine, live include:

• difficulty breathing
• hoarseness or wheezing
• hives
• dizziness, weakness, or fast heartbeat
• muscle cramps
• seizures
• sweating
• swelling of the face, ankles, or hands
• swollen joints

Rare side effects of Chikungunya vaccine, live include:

• none 

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, coordination loss, unsteady, very stiff muscles, high fever, profuse sweating, or tremors.
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights.
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, lightheadedness, or passing out.

This is not a complete list of side effects and other serious side effects or health problems that may occur because of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult dosage

Injectable, lyophilized powder for reconstitution

• Each single-dose vial contains a live lyophilized antigen component
• Packaged with a prefilled ungraduated syringe of sterile water diluent component

Chikungunya virus

Adult dosage

• 0.5 mL IM x 1 dose

Dosage Considerations – Should be Given as Follows: 

• See “Dosages”

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, healthcare provider, or pharmacist first.

• Chikungunya vaccine, live has no noted severe interactions with any other drugs
• Chikungunya vaccine, live has no noted serious interactions with any other drugs
• Chikungunya vaccine, live has no noted moderate interactions with any other drugs
• Chikungunya vaccine, live has no noted minor interactions with any other drugs

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all the products you use. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice, health questions, or concerns.

Contraindications

• Individuals who are immunodeficient or immunosuppressed due to disease or medical therapy (eg, from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy, or patients with HIV infection who are severely immunocompromised)
• History of severe allergic reactions (Anaphylaxis) to any component of the vaccine

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Chikungunya vaccine, live?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Chikungunya vaccine, live?”

Cautions

• Administer in a setting that provides appropriate medical treatment used to manage immediate allergic reactions
• Vaccination may cause severe or prolonged chikungunya-like adverse reactions
• Syncope (fainting) may occur; procedures should be in place to avoid injury from fainting
• Vaccination may not protect all individuals
• Potential for vertical transmission of vaccine virus and fetal/neonatal adverse reactions
• Vertical transmission of wild-type CHIKV infection to neonates from pregnant individuals with viremia at delivery is common and can cause severe, potentially fatal CHIKV disease in neonates
• Vertical transmission of wild-type CHIKV and fetal death attributable to CHIKV in the context of antepartum infection is infrequent
• Vaccine viremia occurs in the first week following administration, with a resolution of viremia by 14 days after vaccination 
• Unknown if vaccine virus can be transmitted from a pregnant woman to the fetus or neonate and cause fetal or neonatal adverse reactions
• Decisions to administer during pregnancy should take into consideration the individual risk of exposure to wild-type CHIKV, gestational age, and risks to the fetus or neonate from vertical transmission of wild-type CHIKV
• Closely monitor neonates for 7 days after birth for potential disease due to vaccine virus if they are born within 14 days of their mother receiving the vaccine

Pregnancy and Lactation

• There are no adequate and well-controlled studies on pregnant women, and human data available from clinical trials are insufficient to establish the presence or absence of vaccine-associated risk during pregnancy
• Pregnancy registry
  • Pregnant patients who received the vaccine or their clinicians should contact OXON Epidemiology at 1-855-417-6214 to enroll in or obtain information about the registry
• Clinical considerations
  • Disease-associated maternal and/or embryo/fetal risk
  • Vertical transmission of wild-type CHIKV to neonates from pregnant individuals with viremia at delivery is common and can cause severe, potentially fatal CHIKV disease in neonates, with neurologic (eg, encephalopathy, intracranial hemorrhage) and myocardial manifestations
  • Vertical transmission of wild-type CHIKV and fetal death attributable to CHIKV in the context of antepartum infection has been reported to occur infrequently
• Fetal/neonatal adverse reactions
  • Vaccine viremia occurred in the first week following administration, with resolution of viremia by 14 days after vaccination
  • Unknown if vaccine virus can be transmitted from a pregnant individual to a fetus or neonate and cause fetal or neonatal adverse reactions
  • Decisions to administer during pregnancy should take into consideration the individual’s risk of exposure to wild-type CHIKV, gestational age, and risks to the fetus or neonate from vertical transmission of wild-type CHIKV
  • Closely monitor neonates for 7 days after birth
• Lactation
  • Human data are not available to assess the vaccine’s effects on milk production, its presence in breast milk, or its effects on breastfed children
• Clinical considerations
  • Vaccine viremia occurs after vaccination
  • In a clinical trial, the vaccine virus was not detectable at 14 days after vaccination